Stocks and Investing
Stocks and Investing
Wed, March 16, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, March 15, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tazeen Ahmad Upgraded (ASND) to Strong Buy and Increased Target to $161 on, Mar 15th, 2022
Tazeen Ahmad of B of A Securities, Upgraded "Ascendis Pharma A/S" (ASND) to Strong Buy and Increased Target from $148 to $161 on, Mar 15th, 2022.
Tazeen has made no other calls on ASND in the last 4 months.
There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 1 agrees with Tazeen's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Yaron Werber of "Cowen & Co." Initiated at Hold and Held Target at $136 on, Thursday, January 6th, 2022
These are the ratings of the 4 analyists that currently disagree with Tazeen
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $194 on, Monday, March 14th, 2022
- Derek Archila of "Wells Fargo" Maintained at Buy with Decreased Target to $170 on, Thursday, March 3rd, 2022
- Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $117 on, Thursday, March 3rd, 2022
- Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $170 on, Monday, February 14th, 2022
Contributing Sources